Ken Nesmith

Ken Nesmith has been active in healthcare and life sciences as a technologist and executive for over 15 years. He was the co-founder and CEO of Lexent Bio, a leading liquid biopsy company focused on solid tumor cancer diagnostics, acquired by Foundation Medicine in 2020. Prior to Lexent Bio, he led product strategy at Counsyl, leading a team of clinical and software product managers. He built his career in health and technology at companies including Noom, Boston Consulting Group, Goldman Sachs, and Codon Devices. He completed undergraduate studies at MIT and an MBA at Wharton.